AgomAb Therapeutics N.V. American Depositary Shares
AGMB
NASDAQ·Healthcare·Biotechnology·Mkt cap $777.1M
$15.78
▲ +6.41%
P/E
—
Mkt Cap
$777.1M
52-Wk Range
$8.75–$17.82
52-Week Range
$8.75 - $17.82
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+59.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AGMB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 6, 2026
Reported EPS of -$0.45 vs -$0.38 consensus (-16.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-16.2%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 25, 2026
vs Industry
How AGMB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.